Literature DB >> 27699010

Changes in c-Kit expression levels during the course of radiation therapy for nasopharyngeal carcinoma.

Feng Jiang1, Wei Hu2, Bicheng Zhang3, Jing Xu3, Yongjie Shui3, Xiaofeng Zhou2, Xiaoqiu Ren2, Xiaozhong Chen4, Li Shen5, Qichun Wei5.   

Abstract

In the era of intensity-modulated radiotherapy, distant metastasis is currently the main cause of treatment failure for nasopharyngeal carcinoma (NPC). Additional therapeutic strategies are required to control the metastasis and improve survival. One strategy is targeted therapy, for example against c-Kit. In the current study, the frequency of c-Kit expression was determined immunohistochemically in 106 NPC patients. c-Kit expression changes during the course of radiation therapy were detected in 41 cases via weekly biopsy. Twelve cases (11.3%) had c-Kit expression scores of 3+ and 16 (15.1%) had scores of 2+. Thus, c-Kit overexpression (2+ or 3+) was observed in 28 (26.4%) patients. There were 35 (33.0%) and 43 (40.6%) patients with c-Kit expression scores of 1+ and 0, respectively. Furthermore, a trend of decreased c-Kit expression was observed after commencing radiotherapy according to the 41 NPC patients who were biopsied weekly. Therefore, c-Kit overexpression was identified to be common in NPC, and evaluating c-Kit as a therapeutic target for metastatic NPC via c-Kit overexpression subsequent to first line treatment may be of interest. To the best of our knowledge, the present study is the first to demonstrate a trend of decreased c-Kit expression during the course of radiotherapy.

Entities:  

Keywords:  c-Kit; metastasis; nasopharyngeal carcinoma; radiotherapy; targeted therapy

Year:  2016        PMID: 27699010      PMCID: PMC5038864          DOI: 10.3892/br.2016.757

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  18 in total

1.  How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?

Authors:  Shu-Zhen Lai; Wen-Fei Li; Lei Chen; Wei Luo; Yuan-Yuan Chen; Li-Zhi Liu; Ying Sun; Ai-Hua Lin; Meng-Zhong Liu; Jun Ma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-17       Impact factor: 7.038

2.  C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines.

Authors:  Pei-Yu Huang; Ming-Huang Hong; Xing Zhang; Hai-Qiang Mai; Dong-Hua Luo; Li Zhang
Journal:  Chin J Cancer       Date:  2010-02

3.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Authors:  Ramzi Dagher; Martin Cohen; Gene Williams; Mark Rothmann; Jogarao Gobburu; Gabriel Robbie; Atiqur Rahman; Gang Chen; Ann Staten; Donna Griebel; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

4.  Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Authors:  Edwin Pun Hui; Vivian W Y Lui; Cesar S C Wong; Brigette B Y Ma; Cecilia P Y Lau; Crystal S F Cheung; Kakiu Ho; Suk-Hang Cheng; Margaret H L Ng; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2010-05-15       Impact factor: 3.850

5.  Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium.

Authors:  Lai-Fa Sheu; Wen-Cheng Lee; Herng-Sheng Lee; Woei-Yau Kao; Ann Chen
Journal:  J Pathol       Date:  2005-10       Impact factor: 7.996

6.  Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience.

Authors:  Anne W M Lee; W M Sze; Joseph S K Au; S F Leung; T W Leung; Daniel T T Chua; Benny C Y Zee; Stephen C K Law; Peter M L Teo; Stewart Y Tung; Dora L W Kwong; W H Lau
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

7.  Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach.

Authors:  G Bar-Sela; A Kuten; S Ben-Eliezer; E Gov-Ari; O Ben-Izhak
Journal:  Mod Pathol       Date:  2003-10       Impact factor: 7.842

8.  Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer.

Authors:  Ulrich-Peter Rohr; Nina Rehfeld; Lucy Pflugfelder; Helene Geddert; Wolfram Müller; Ulrich Steidl; Roland Fenk; Thorsten Gräf; Matthias Schott; Klaus-Peter Thiele; Helmut Erich Gabbert; Ulrich Germing; Ralf Kronenwett; Rainer Haas
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

9.  Design of a prognostic index score for metastatic nasopharyngeal carcinoma.

Authors:  Y K Ong; D M Heng; B Chung; S S Leong; J Wee; K W Fong; T Tan; E H Tan
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

10.  Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

Authors:  Y Yarden; W J Kuang; T Yang-Feng; L Coussens; S Munemitsu; T J Dull; E Chen; J Schlessinger; U Francke; A Ullrich
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  1 in total

1.  Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.

Authors:  Qiuyan Chen; Linquan Tang; Na Liu; Feng Han; Ling Guo; Shanshan Guo; Jianwei Wang; Huai Liu; Yanfang Ye; Lu Zhang; Liting Liu; Pan Wang; Yingqin Li; Qingmei He; Xiaoqun Yang; Qingnan Tang; Yang Li; YuJing Liang; XueSong Sun; Chuanmiao Xie; Yunxian Mo; Ying Guo; Rui Sun; Haoyuan Mo; Kajia Cao; Xiang Guo; Musheng Zeng; Haiqiang Mai; Jun Ma
Journal:  Cancer Commun (Lond)       Date:  2018-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.